Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Developments Influencing Industry Expansion Through 2030
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Change Between 2026 And 2030?
The adeno-associated virus (avv) vectors in gene therapy market size has demonstrated rapid expansion in recent years. This market is forecasted to grow from $3.16 billion in 2025 to $3.7 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.3%. The historical increase in market size can be attributed to developments in viral vector safety, enhanced research into rare genetic disorders, successful clinical gene therapy applications, various regulatory approvals, and sustained investments in academic research.
The adeno-associated virus (avv) vectors in gene therapy market is anticipated to witness significant expansion in the coming years. It will grow to $6.99 billion in 2030 at a compound annual growth rate (CAGR) of 17.2%. This expansion during the projected timeframe is driven by factors such as the introduction of commercial gene therapies, the need for scalable vector production, the proliferation of precision medicine, encouragement from orphan drug incentives, and an increase in global clinical trials. Notable trends for the forecast period feature the expansion of gene augmentation therapies, increasing demand for rare disease gene treatments, the growing adoption of in vivo gene delivery, enhanced commercial-scale vector manufacturing, and a concentrated effort on achieving long-term therapeutic durability.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp
What Influential Factors Are Boosting The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Demand?
The increasing emphasis on gene-based therapies is anticipated to stimulate the expansion of adeno-associated virus (AAV) vectors within the gene therapy market. Gene-based therapies involve medical interventions that alter or manipulate genes to combat, manage, or cure illnesses at a molecular level. Progress in genetic research underpins this growing focus, as such advancements enhance the precision and efficacy of gene editing methods. Adeno-associated virus (AAV) vectors in gene therapy facilitate the creation of gene-based therapies by ensuring the secure and efficient delivery of therapeutic genes into target cells, primarily due to their low immunogenicity and capacity for sustained gene expression. As an illustration, in 2023, IQVIA, a US-based provider of advanced analytics and technology solutions for the life sciences industry, reported that global spending on cell and gene therapies reached $5.9 billion, marking a 38% increase from 2022. Consequently, the heightened focus on developing gene-based therapies is propelling the growth of the adeno-associated virus (AAV) vectors market.
What Are The Major Segment Categories Within The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
The adeno-associated virus (avv) vectors in gene therapy market covered in this report is segmented –
1) By Type of Therapy: Gene Augmentation, Immunotherapy, Other Type of Therapy
2) By Type of Gene Delivery Method Used: Ex Vivo, In Vivo
3) By Scale of Operation: Preclinical, Clinical, Commercial
4) By Target Therapeutic Area: Genetic Disorders, Hematological Disorders, Infectious Diseases, Metabolic Disorders, Ophthalmic Disorders, Muscle Disorders, Neurological Disorders, Other Target Therapeutic Area
Subsegments:
1) By Gene Augmentation: Monogenic Disorders, Neurological Disorders, Muscular Disorders, Ophthalmological Disorders, Metabolic Disorders
2) By Immunotherapy: Oncology, Infectious Diseases, Autoimmune Disorders, Vaccine Development, T-Cell Engineering
3) By Other Type of Therapy: Gene Editing Support, RNA Interference, Neuroprotection and Neuroregeneration, Anti-Inflammatory Applications, Regenerative Medicine
What Trends Are Influencing The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
Companies operating within the adeno-associated virus (AAV) vectors in the gene therapy market are concentrating on advanced innovations, such as the adaptation of vector diversity for assay versatility. This strategic focus is intended to improve target tissue specificity, heighten therapeutic efficacy, and expedite the creation of customized gene therapies for a broad spectrum of indications. Tailored vector diversity for assay versatility signifies the utilization of multiple AAV serotypes or constructs to support a variety of analytical tests and therapeutic applications. Illustratively, in May 2024, Charles River Laboratories, a US-based pharmaceutical company, launched novel reference materials for adeno-associated virus (AAV) and lentiviral vectors (LVV). These materials are designed to cater to the expanding requirements of cell and gene therapy (CGT) development. The portfolio aids in ensuring a smoother transition from early-stage research to GMP-grade production, contributing to process standardization and improved consistency in viral vector manufacturing. This introduction directly addresses a critical challenge in advancing CGT programs towards successful clinical and commercial implementation.
Who Are The Firms Contributing To The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Ecosystem?
Major companies operating in the adeno-associated virus (avv) vectors in gene therapy market are F. Hoffmann-La Roche Ltd., Sanofi S.A., Novartis AG, Astellas Gene Therapies Inc., Biogen Inc., Sarepta Therapeutics Inc., Oxford BioMedica plc, Rocket Pharmaceuticals Inc., Aldevron LLC, REGENXBIO Inc., uniQure N.V., Passage Bio Inc., Voyager Therapeutics Inc., Dyno Therapeutics Inc., MeiraGTx Holdings plc, Abeona Therapeutics Inc., 4D Molecular Therapeutics Inc., GenSight Biologics S.A., Taysha Gene Therapies Inc., LogicBio Therapeutics Inc.
Access The Complete Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report:
Which Region Commands The Largest Share Of The Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market?
North America was the largest region in the adeno-associated virus (AVV) vectors in gene therapy market in 2025. The regions covered in the adeno-associated virus (avv) vectors in gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24135&type=smp
Browse Through More Reports Similar to the Global Adeno-Associated Virus (AVV) Vectors In Gene Therapy Market 2026, By The Business Research Company
Adeno Associated Viral Vectors Market Report 2026
Nucleic Acid Based Gene Therapy Market Report 2026
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
